Indofarma (Persero) Tbk PT operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Indofarma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Hyundai Pharmaceutical Company Limited
of South Korea
sales of 133.94 billion Korean Won [US$112.78 million]
of which 88%
Standard Chem. & Pharm. Co Ltd
(3.57 billion Taiwanese Dollars [US$115.48 million]
of which 58%
was Pharmaceuticals), and
Shandong Wohua Pharmaceutical Co., Ltd.
based in China
(774.40 million Chinese Renmimbi [US$109.19 million]
of which 100%
was Medical Industry).
During the year ended December of 2018, sales at
Indofarma (Persero) Tbk PT were 1.59 trillion Indonesian Rupiahs (US$112.94 million).
decrease of 2.4%
versus 2017, when the company's sales were 1.63 trillion Indonesian Rupiahs.
Contributing to the drop in overall sales was the 72.2% decline
in Medical Devices, from 862.14 billion Indonesian Rupiahs to 239.49 billion Indonesian Rupiahs.
However, these declines were partially offset by the increase in sales of
Medicine (up 76.0% to 1.35 trillion Indonesian Rupiahs)
Engineering Pharmaceutical (up 13.7% to 661.39 million Indonesian Rupiahs)